ProfileGDS5678 / 1449162_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 72% 72% 72% 75% 72% 73% 72% 72% 72% 73% 72% 72% 72% 73% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.6083372
GSM967853U87-EV human glioblastoma xenograft - Control 24.6214772
GSM967854U87-EV human glioblastoma xenograft - Control 34.6165872
GSM967855U87-EV human glioblastoma xenograft - Control 45.0770875
GSM967856U87-EV human glioblastoma xenograft - Control 54.6042872
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.6259673
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.5878272
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.6011572
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.6294872
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.7441573
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.6059472
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.5992172
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.6195572
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.6811773